| Name | Title | Contact Details |
|---|
Pacificord is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met.
Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat glioblastoma, uveal melanoma, low grade gliomas. We anticipate tests for thymoma and esophageal cancer to be on the market in the near future (1Q-1H, 2012) as they are going through final validation.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click is also progressing a broad pipeline of prescription Digital Therapeutics across a variety of high-burden therapeutic areas, including Major Depressive Disorder, Schizophrenia, Acute Coronary Syndrome, Migraine, Chronic Pain, Insomnia, COPD, Obesity, and more.